following a resubmission:
racecadotril (Hidrasec Infants®, Hidrasec Children®) is not recommended for use within NHS Scotland.
Indication under review: Complementary symptomatic treatment of acute diarrhoea in infants older than three months and in children, together with oral rehydration and the usual support measures, when these measures alone are insufficient to control the clinical condition and when causal treatment is not possible. If causal treatment is possible racecadotril can be administered as a complementary treatment.
In a meta-analysis, racecadotril was significantly better than placebo in reducing the duration of diarrhoea and stool output in children with acute diarrhoea. There is insufficient evidence that it improves recovery rate.
The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.
Download detailed advice180KB (PDF)
Medicine details
- Medicine name:
- racecadotril (Hidrasec)
- SMC ID:
- 818/12
- Indication:
- Complementary symptomatic treatment of acute diarrhoea in infants older than three months and in children, together with oral rehydration and the usual support measures, when these measures alone are insufficient to control the clinical condition and when causal treatment is not possible. If causal treatment is possible racecadotril can be administered as a complementary treatment.
- Pharmaceutical company
- Abbott Healthcare Products Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 11 August 2014